Amit Roy

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 23

Top Venues

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

Clinical cancer research : an official journal of the American Association for Cancer Research

Scientific reports

Bristol Myers Squibb Co

Rutgers The State University of New Jersey (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Bristol Myers Squibb Co

United States

Group Director :: Clinical Pharmacology & Pharmacometrics

Vertex Pharmaceuticals Inc

United States

Clinical Pharmacologist/Pharmacometrician :: Clinical Pharmacology

Education History

Rutgers The State University of New Jersey

United States

PHD :: Chemical & Biochemical Engineering

University of Michigan

United States

BSC :: Chemical Engineering

Hindu College New Delhi

India

BSC :: Chemistry

Publications

Zheyi Hu, Sihang Liu, Yue Zhao, Shengnan Du, Lora Hamuro, Jun Shen, Amit Roy, Li Zhu
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Zheyi Hu, Sihang Liu, Yue Zhao, Shengnan Du, Lora Hamuro, Jun Shen, Amit Roy, Li Zhu
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Zheyi Hu, Sihang Liu, Yue Zhao, Shengnan Du, Lora Hamuro, Jun Shen, Amit Roy, Li Zhu
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Yue Zhao, Kinjal Sanghavi, Amit Roy, Bindu Murthy, Akintunde Bello, Urvi Aras, Heather Vezina
Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors. Clinical pharmacology and therapeutics 115 (3) (2024)
Yue Zhao, Kinjal Sanghavi, Amit Roy, Bindu Murthy, Akintunde Bello, Urvi Aras, Heather Vezina
Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors. Clinical pharmacology and therapeutics 115 (3) (2024)
Yue Zhao, Kinjal Sanghavi, Amit Roy, Bindu Murthy, Akintunde Bello, Urvi Aras, Heather Vezina
Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors. Clinical pharmacology and therapeutics 115 (3) (2024)
Yue Zhao, Zheyi Hu, Sai Praneeth Bathena, Sarah Keidel, Karen Miller-Moslin, Paul Statkevich, Akintunde Bello, Amit Roy, Satyendra Suryawanshi
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Yue Zhao, Zheyi Hu, Sai Praneeth Bathena, Sarah Keidel, Karen Miller-Moslin, Paul Statkevich, Akintunde Bello, Amit Roy, Satyendra Suryawanshi
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Yue Zhao, Zheyi Hu, Sai Praneeth Bathena, Sarah Keidel, Karen Miller-Moslin, Paul Statkevich, Akintunde Bello, Amit Roy, Satyendra Suryawanshi
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (14) (2024)
Zheyi Hu, Sihang Liu, Yue Zhao, Shengnan Du, Lora Hamuro, Jun Shen, Amit Roy, Li Zhu
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Zheyi Hu, Sihang Liu, Yue Zhao, Shengnan Du, Lora Hamuro, Jun Shen, Amit Roy, Li Zhu
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect. CPT: pharmacometrics & systems pharmacology 13 (3) (2024)
Samira M Garonzik, David H Salinger, Maria Palmisano, Amy J Sehnert, Neelima Thanneer, Hyunmoon Back, Julie D Seroogy, Daniel D Gretler, Amit Roy, Vidya Perera
Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy. CPT: pharmacometrics & systems pharmacology (2024)
Yue Zhao, Zheyi Hu, Sai Praneeth Bathena, Sarah Keidel, Karen Miller-Moslin, Paul Statkevich, Akintunde Bello, Amit Roy, Satyendra Suryawanshi
Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Peter Chang, Vidya Perera, David H Salinger, Samira M Garonzik, Neelima Thanneer, Hyunmoon Back, Julie D Seroogy, Daniel D Gretler, Amy J Sehnert, Maria Palmisano, Amit Roy
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration. CPT: pharmacometrics & systems pharmacology (2024)
Zheyi Hu, Sihang Liu, Yue Zhao, Shengnan Du, Lora Hamuro, Jun Shen, Amit Roy, Li Zhu
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-Going beyond the body-size effect. CPT: pharmacometrics & systems pharmacology (2023)
Sihem Ait-Oudhia, Yow-Ming C Wang, Anne-Gaelle Dosne, Amit Roy, Jin Y Jin, Jun Shen, Leonid Kagan, Flora T Musuamba, Lucia Zhang, Shinichi Kijima, Marc R Gastonguay, Daniele Ouellet
Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics. Clinical pharmacology and therapeutics (2023)
Shengnan Du, Yue Zhao, Zheyi Hu, Sihang Liu, Amit Roy, Jun Shen, Li Zhu, Lora Hamuro
Pediatric model-based dose optimization using a pooled exposure-response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma. CPT: pharmacometrics & systems pharmacology (2023)
Zheyi Hu, Sihang Liu, Yue Zhao, Shengnan Du, Lora Hamuro, Jun Shen, Amit Roy, Li Zhu
Nivolumab and ipilimumab population pharmacokinetics in support of pediatric dose recommendations-going beyond the body-size effect. CPT: pharmacometrics & systems pharmacology (2023)
Yue Zhao, Kinjal Sanghavi, Amit Roy, Bindu Murthy, Akintunde Bello, Urvi Aras, Heather Vezina
Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors. Clinical pharmacology and therapeutics (2023)
Yue Zhao, Kinjal Sanghavi, Amit Roy, Bindu Murthy, Akintunde Bello, Urvi Aras, Heather Vezina
Model-Based Dose Selection of Subcutaneous Nivolumab in Patients with Advanced Solid Tumors. Clinical pharmacology and therapeutics (2023)
Kinjal Sanghavi, Pradeep Vuppala, Vijay D Ivaturi, Lora Hamuro, Amit Roy, Satyendra Suryawanshi
Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology. CPT: pharmacometrics & systems pharmacology 10 (7) (2021)
Gaurav Bajaj, Satyendra Suryawanshi, Amit Roy, Manish Gupta
Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology. British journal of clinical pharmacology 85 (9) (2019)
Ingmar Glauche, Matthias Kuhn, Christoph Baldow, Philipp Schulze, Tino Rothe, Hendrik Liebscher, Amit Roy, Xiaoning Wang, Ingo Roeder
Quantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparison. Scientific reports 8 (1) (2018)

Amit Roy.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Amit Roy